(Bloomberg) — Eli Lilly & Co. said the potential safety concern that triggered a pause of a high-profile government-sponsored clinical trial of an experimental Covid-19 antibody treatment hasn’t affected its other studies.
On Tuesday, Lilly said enrollment in a trial of its monoclonal antibody treatment sponsored by the National Institutes of Health had been paused due to a potential safety concern.
While that trial, known as ACTIV-3, remains in limbo, the Indianapolis-based drugmaker said on Wednesday that the independent data safety monitoring board that recommended the pause hasn’t called for enrollment to be paused in another government-run trial it is overseeing, known as ACTIV-2.
“At this time, only the DSMB has reviewed the data from the trial, and NIH leadership and Lilly remain blinded to the ongoing trial results,” the company said in a statement on its website. “Lilly trusts the judgment of the independent DSMB and supports its decisions to exercise caution in ensuring the safety of the patients participating in this study.
Shares of Eli Lilly declined 0.2% to $149.72 at 9:35 a.m. in New York on Wednesday.
For more articles like this, please visit us at bloomberg.com
©2020 Bloomberg L.P.